Clinical relevance and therapeutic significance of MicroRNA-133a expression profiles and functions in malignant osteosarcoma-initiating cells

Stem Cells

Volumn 32, Issue 4, 2014, Pages 959-973

  Fujiwara, Tomohiro ^a,b,c   Katsuda, Takeshi ^a   Hagiwara, Keitaro ^a   Kosaka, Nobuyoshi ^a   Yoshioka, Yusuke ^a   Takahashi, Ryou U ^a   Takeshita, Fumitaka ^a   Kubota, Daisuke ^a   Kondo, Tadashi ^a   Ichikawa, Hitoshi ^a   Yoshida, Akihiko ^b   Kobayashi, Eisuke ^b   Kawai, Akira ^b   Ozaki, Toshifumi ^c   Ochiya, Takahiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

Clinical translation; Locked nucleic acid; MicroRNA; Osteosarcoma

Indexed keywords

CD133 ANTIGEN; CISPLATIN; LOCKED NUCLEIC ACID; LOCKED NUCLEIC ACID MICRO RNA 133A; MICRORNA; MICRORNA 133A; UNCLASSIFIED DRUG; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MIRN133 MICRORNA, HUMAN; PEPTIDE; RNA; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CELL INVASION; CELL POPULATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LUNG METASTASIS; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PHENOTYPE; REGULATORY MECHANISM; ADULT; ANIMAL; BIOSYNTHESIS; BONE NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; LUNG NEOPLASMS; MALE; METABOLISM; MORTALITY; NUDE MOUSE; PATHOLOGY; SCID MOUSE; SECONDARY; SURVIVAL RATE; TUMOR INVASION;

ADULT; ANIMALS; ANTIGENS, CD; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MICE, SCID; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; OSTEOSARCOMA; PEPTIDES; RNA, NEOPLASM; SURVIVAL RATE;

EID: 84896371663     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1618     Document Type: Article

References (69)

1. Aogi K, Woodman A, Urquidi V, et al. Telomerase activity in soft-tissue and bone sarcomas. Clin Cancer Res 2000; 6: 4776-4781.
2. Fletcher CD,. The evolving classification of soft tissue tumours: An update based on the new WHO classification. Histopathology 2006; 48: 3-12.
3. Naka N, Takenaka S, Araki N, et al. Synovial sarcoma is a stem cell malignancy. Stem Cells 2010; 28: 1119-1131.
4. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
5. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-Perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66: 9339-9344.
6. Clevers H,. The cancer stem cell: Premises, promises and challenges. Nat Med 2011; 17: 313-319.
7. Visvader JE, Lindeman GJ,. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-768.
8. Allison DC, Carney SC, Ahlmann ER, et al. A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012; 2012: 704872.
9. Kawaguchi N, Ahmed AR, Matsumoto S, et al. The concept of curative margin in surgery for bone and soft tissue sarcoma. Clin Orthop Relat Res 2004: 165-172.
10. Gupta A, Meswania J, Pollock R, et al. Non-invasive distal femoral expandable endoprosthesis for limb-salvage surgery in paediatric tumours. J Bone Joint Surg 2006; 88: 649-654.
11. Bacci G, Rocca M, Salone M, et al. High grade osteosarcoma of the extremities with lung metastases at presentation: Treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol 2008; 98: 415-420.
12. Halldorsson A, Brooks S, Montgomery S, et al. Lung metastasis 21 years after initial diagnosis of osteosarcoma: A case report. J Med Case Rep 2009; 3: 9298.
13. Adhikari AS, Agarwal N, Wood BM, et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 2010; 70: 4602-4612.
14. Basu-Roy U, Seo E, Ramanathapuram L, et al. Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas. Oncogene 2012; 31: 2270-2282.
15. Gibbs CP, Kukekov VG, Reith JD, et al. Stem-like cells in bone sarcomas: Implications for tumorigenesis. Neoplasia 2005; 7: 967-976.
16. Levings PP, McGarry SV, Currie TP, et al. Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res 2009; 69: 5648-5655.
17. Siclari VA, Qin L,. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res 2010; 5: 78.
18. Tirino V, Desiderio V, d'Aquino R, et al. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PloS one 2008; 3: e3469.
19. Tirino V, Desiderio V, Paino F, et al. Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J 2011; 25: 2022-2030.
20. Wilson H, Huelsmeyer M, Chun R, et al. Isolation and characterisation of cancer stem cells from canine osteosarcoma. Vet J 2008; 175: 69-75.
21. Wu C, Wei Q, Utomo V, et al. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res 2007; 67: 8216-8222.
22. Gregory RI, Shiekhattar R,. MicroRNA biogenesis and cancer. Cancer Res 2005; 65: 3509-3512.
23. Ambros V,. microRNAs: Tiny regulators with great potential. Cell 2001; 107: 823-826.
24. Calin GA, Croce CM,. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
25. Esquela-Kerscher A, Slack FJ,. Oncomirs-MicroRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
26. Ma S, Tang KH, Chan YP, et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010; 7: 694-707.
27. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. New Engl J Med 2005; 353: 1793-1801.
28. Jiang J, Gusev Y, Aderca I, et al. Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008; 14: 419-427.
29. Kawai A, Ozaki T, Ikeda S, et al. Two distinct cell lines derived from a human osteosarcoma. J Cancer Res Clin Oncol 1989; 115: 531-536.
30. Osaki M, Takeshita F, Sugimoto Y, et al. MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther 2011; 19: 1123-1130.
31. Youden W,. Index for rating diagnostic tests. Cancer 1950; 3: 32-35.
32. Gires O,. Lessons from common markers of tumor-initiating cells in solid cancers. Cell Mol Life Sci 2011; 68: 4009-4022.
33. Cao Y, Zhou Z, de Crombrugghe B, et al. Osterix, a transcription factor for osteoblast differentiation, mediates antitumor activity in murine osteosarcoma. Cancer Res 2005; 65: 1124-1128.
34. de Crombrugghe B, Lefebvre V, Behringer RR, et al. Transcriptional mechanisms of chondrocyte differentiation. Matrix Biol 2000; 19: 389-394.
35. Ducy P, Zhang R, Geoffroy V, et al. Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747-754.
36. Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002; 108: 17-29.
37. Tang N, Song WX, Luo J, et al. Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 2008; 466: 2114-2130.
38. Croce CM,. Causes and consequences of microRNA dysregulation in cancer. Nat Rev. Genet 2009; 10: 704-714.
39. Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452: 896-899.
40. Haraguchi T, Nakano H, Tagawa T, et al. A potent 2′-O-methylated RNA-based microRNA inhibitor with unique secondary structures. Nucleic Acids Res 2012; 40: e58.
41. Obad S, dos Santos CO, Petri A, et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 2011; 43: 371-378.
42. Dass CR, Ek ET, Choong PF,. Human xenograft osteosarcoma models with spontaneous metastasis in mice: Clinical relevance and applicability for drug testing. J Cancer Res Clin Oncol 2007; 133: 193-198.
43. Kimura K, Nakano T, Park Y-B, et al. Establishment of human osteosarcoma cell lines with high metastatic potential to lungs and their utilities for therapeutic studies on metastatic osteosarcoma. Clin Exp Metastasis 2002; 19: 477-486.
44. Tsuchida R, Das B, Yeger H, et al. Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling. Oncogene 2008; 27: 3923-3934.
45. Gostissa M, Hengstermann A, Fogal V, et al. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J 1999; 18: 6462-6471.
46. Nguyen LN, Holdren MS, Nguyen AP, et al. Sorting nexin 1 down-regulation promotes colon tumorigenesis. Clin Cancer Res 2006; 12: 6952-6959.
47. Ségui B, Andrieu-Abadie N, Jaffrézou J-P, et al. Sphingolipids as modulators of cancer cell death: Potential therapeutic targets. Biochim Biophys Acta 2006; 1758: 2104-2120.
48. Gillette JM, Chan DC, Nielsen-Preiss SM,. Annexin 2 expression is reduced in human osteosarcoma metastases. J Cell Biochem 2004; 92: 820-832.
49. Shackleton M, Quintana E, Fearon ER, et al. Heterogeneity in cancer: Cancer stem cells versus clonal evolution. Cell 2009; 138: 822-829.
50. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90: 5002-5012.
51. Marzesco AM, Janich P, Wilsch-Brauninger M, et al. Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. J Cell Sci 2005; 118: 2849-2858.
52. Uchida N, Buck DW, He D, et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA 2000; 97: 14720-14725.
53. Freund D, Bauer N, Boxberger S, et al. Polarization of human hematopoietic progenitors during contact with multipotent mesenchymal stromal cells: Effects on proliferation and clonogenicity. Stem Cells Dev 2006; 15: 815-829.
54. Ma L, Reinhardt F, Pan E, et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 2010; 28: 341-347.
55. Ma L, Teruya-Feldstein J, Weinberg RA,. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682-688.
56. Preis M, Gardner TB, Gordon SR, et al. MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res 2011; 17: 5812-5821.
57. Gabriely G, Yi M, Narayan RS, et al. Human glioma growth is controlled by microRNA-10b. Cancer Res 2011; 71: 3563-3572.
58. Chen JF, Mandel EM, Thomson JM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006; 38: 228-233.
59. Deng Z, Chen JF, Wang DZ,. Transgenic overexpression of miR-133a in skeletal muscle. BMC Musculoskelet Disord 2011; 12: 115.
60. Heddleston JM, Li Z, Lathia JD, et al. Hypoxia inducible factors in cancer stem cells. Br J Cancer 2010; 102: 789-795.
61. Iida H, Suzuki M, Goitsuka R, et al. Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. Int J Oncol 2012; 40: 71-79.
62. Soeda A, Park M, Lee D, et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009; 28: 3949-3959.
63. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327: 198-201.
64. Kim M, Kasinski AL, Slack FJ,. MicroRNA therapeutics in preclinical cancer models. Lancet Oncol 2011; 12: 319-321.
65. Zhang Y, Roccaro AM, Rombaoa C, et al. LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood 2012; 120: 1678-1686.
66. Huitema K, van den Dikkenberg J, Brouwers JFHM, et al. Identification of a family of animal sphingomyelin synthases. EMBO J 2004; 23: 33-44.
67. Hay RT,. SUMO. A history of modification. Mol Cell 2005; 18: 1-12.
68. Balch C, Dedman JR,. Annexins II and V inhibit cell migration. Exp Cell Res 1997; 237: 259-263.
69. Mintz MB, Sowers R, Brown KM, et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 2005; 65: 1748-1754.